Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia
Brain · 01.08.2023 · 146 (8) · 3221-3231
DOI: 10.1093/brain/awad078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 08.03.2023. Verfasst von Maura Malpetti und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 0SZ, UK. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Neurodegenerative Diseases, Pick Disease of the Brain, Cognitive Dysfunction. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Department of Health, Race Against Dementia Alzheimer’s Research.
Themen: Demenz
Abstract (Originalsprache)
Frontotemporal dementia is clinically and neuropathologically heterogeneous, but neuroinflammation, atrophy and cognitive impairment occur in all of its principal syndromes. Across the clinical spectrum of frontotemporal dementia, we assess the predictive value of in vivo neuroimaging measures of microglial activation and grey-matter volume on the rate of future cognitive decline. We hypothesized that inflammation is detrimental to cognitive performance, in addition to the effect of atrophy. Thirty patients with a clinical diagnosis of frontotemporal dementia underwent a baseline multimodal imaging assessment, including [11C]PK11195 PET to index microglial activation and structural MRI to quantify grey-matter volume. Ten people had behavioural variant frontotemporal dementia, 10 had the semantic variant of primary progressive aphasia and 10 had the non-fluent agrammatic variant of primary progressive aphasia. Cognition was assessed at baseline and longitudinally with the revised Addenbrooke's Cognitive Examination, at an average of 7-month intervals (for an average of ∼2 years, up to ∼5 years). Regional [11C]PK11195 binding potential and grey-matter volume were determined, and these were averaged within four hypothesis-driven regions of interest: bilateral frontal and temporal lobes. Linear mixed-effect models were applied to the longitudinal cognitive test scores, with [11C]PK11195 binding potentials and grey-matter volumes as predictors of cognitive performance, with age, education and baseline cognitive performance as covariates. Faster cognitive decline was associated with reduced baseline grey-matter volume and increased microglial activation in frontal regions, bilaterally. In frontal regions, microglial activation and grey-matter volume were negatively correlated, but provided independent information, with inflammation the stronger predictor of the rate of cognitive decline. When clinical diagnosis was included as a factor in the models, a significant predictive effect was found for [11C]PK11195 BPND in the left frontal lobe (−0.70, P = 0.01), but not for grey-matter volumes (P > 0.05), suggesting that inflammation severity in this region relates to cognitive decline regardless of clinical variant. The main results were validated by two-step prediction frequentist and Bayesian estimation of correlations, showing significant associations between the estimated rate of cognitive change (slope) and baseline microglial activation in the frontal lobe. These findings support preclinical models in which neuroinflammation (by microglial activation) accelerates the neurodegenerative disease trajectory. We highlight the potential for immunomodulatory treatment strategies in frontotemporal dementia, in which measures of microglial activation may also improve stratification for clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 0SZ, UK.
- Medical Research Council Cognition and Brain Sciences Unit, Cambridge CB2 7EF, UK.
- Department of Psychiatry, University of Cambridge, Cambridge CB2 0QQ, UK.
- Wolfson Brain Imaging Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
ORCID-Profile: Maura Malpetti, Elijah Mak, Timothy Rittman, Karalyn Patterson, John T O'Brien
Förderung
- Wellcome Trust
- Department of Health
- Race Against Dementia Alzheimer’s Research
- Cambridge University Centre
- National Institute for Health Research
- Cambridge Biomedical Research Centre
- Medical Research Council
- Alzheimer’s Society
Zitieren
APA
Malpetti, M., Cope, T. E., Street, D., Jones, P. S., Hezemans, F. H., Mak, E., Tsvetanov, K. A., Rittman, T., Bevan-Jones, W. R., Patterson, K., Passamonti, L., Fryer, T. D., Hong, Y. T., Aigbirhio, F. I., O'Brien, J. T., & Rowe, J. B. (2023). Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia. Brain, 146(8), 3221-3231. https://doi.org/10.1093/brain/awad078
Vancouver
Malpetti M, Cope TE, Street D, Jones PS, Hezemans FH, Mak E, et al. Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia. Brain. 2023;146(8):3221-3231. doi:10.1093/brain/awad078
BibTeX
@article{Malpetti2023,
author = {Malpetti, Maura and Cope, Thomas E and Street, Duncan and Jones, P Simon and Hezemans, Frank H and Mak, Elijah and Tsvetanov, Kamen A and Rittman, Timothy and Bevan-Jones, W Richard and Patterson, Karalyn and Passamonti, Luca and Fryer, Tim D and Hong, Young T and Aigbirhio, Franklin I and O'Brien, John T and Rowe, James B},
title = {Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia},
journal = {Brain},
year = {2023},
volume = {146},
number = {8},
pages = {3221--3231},
doi = {10.1093/brain/awad078}
}
EUVIMED